Table 2.
Treatment and prognosis of the patients.
| Characteristic | Categories | Number (%) |
|---|---|---|
| Medication of PSS (N = 12) | Glucocorticoid alone | 0 (0 %) |
| Non-glucocorticoid immunosuppressants alone | 4 (33.3 %) | |
| Glucocorticoid + Non-glucocorticoid immunosuppressants | 8 (66.7 %) | |
| hydroxychloroquine | 8 (66.7 %) | |
| CTX | 4 (33.3 %) | |
| AZA | 2 (16.7 %) | |
| MMF | 1 (8.3 %) | |
| methotrexate | 1 (8.3 %) | |
| Medication of stroke (N = 12) | Antiplatelet alone | 5 (41.7 %) |
| Anticoagulation alone | 3 (25.0 %) | |
| Antiplatelet + anticoagulation | 1 (8.3 %) | |
| statin | 6 (41.2 %) | |
| Surgery | EC-IC bypass | 3 (23.1 %) |
| Stenting | 1 (7.7 %) | |
| Length of follow-up (month, N = 9) | Median (range) | 5.0 (1.0–24.0) |
| Initial functional outcome: stroke recurrence (N = 13) | after medication alone (N = 9) | 3 (33.3 %) |
| after surgery (N = 1) | 0 (0 %) | |
| after medication plus surgery (N = 3) | 0 (0 %) | |
| Final functional outcome: improved or uneventful (N = 11) | after medication alone | 7 (63.6 %) |
| after surgery alone | 1 (9.1 %) | |
| after medication plus surgery | 3 (27.3 %) | |
| Vascular Outcome (N = 3) | Aggravation of vascular stenosis | 2 (66.7 %) |
| Alleviation of vessel wall enhancement | 1 (33.3 %) |
PSS: primary Sjögren's-syndrome, CTX: cyclophosphamide, AZA: azathioprine, MMF: mycophenolate mofetil.